China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2015 - 2025)

China Pharma Holdings (CPHI) has reported Asset Writedowns and Impairment for 11 consecutive years, with -$507897.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 10.83% year-over-year to -$507897.0; the trailing twelve-month figure through Dec 2025 stood at -$267184.0 (up 17.84% YoY), and the FY2025 full-year result was -$1018.0, down 117.85% from the prior year.
• Asset Writedowns and Impairment fell to -$507897.0 in Q4 2025 per CPHI's latest filing, from $25302.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $213379.0 in Q1 2025 and bottomed at -$507897.0 in Q4 2025.
• Historically, Asset Writedowns and Impairment has averaged -$52391.2 across 5 years, with a median of -$3007.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment tumbled 5527.31% in 2024, then jumped 1627.9% in 2025.
• Over 5 years, Asset Writedowns and Impairment stood at -$403601.0 in 2021, then jumped by 97.49% to -$10136.0 in 2022, then soared by 183.31% to $8444.0 in 2023, then sank by 5527.31% to -$458282.0 in 2024, then decreased by 10.83% to -$507897.0 in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$507897.0, $25302.0, and $2032.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.